Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myelomaTom Martin, Imtiaz A. Samjoo, Saad Z. Usmani et al.|Current Medical Research and Opinion|2021Cited by 49
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple MyelomaLuciano J. Costa, Parameswaran Hari, Yi Lin et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 45
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myelomaThomas Martin, Sundar Jagannath, Amrita Krishnan et al.|eJHaem|2021Cited by 31
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myelomaTom Martin, Imtiaz A. Samjoo, Saad Z. Usmani et al.|Current Medical Research and Opinion|2022Cited by 25
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple MyelomaKatja Weisel, Kwee Yong, Thomas G. Martin et al.|Clinical Drug Investigation|2021Cited by 23